<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Publications | Jensen Lab</title>
  <link rel="stylesheet" href="style.css" />
</head>
<body>
  <header>
    <h1>Jensen Lab</h1>
    <p>UNC Chapel Hill | Department of Medicine â€“ Division of Cardiology</p>
    <nav>
      <ul>
        <li><a href="index.html">Home</a></li>
        <li><a href="research.html">Research</a></li>
        <li><a href="people.html">People</a></li>
        <li><a href="publications.html">Publications</a></li>
        <li><a href="contact.html">Contact</a></li>
      </ul>
    </nav>
  </header>

  <main>
    <section>
      <h2>Selected Publications</h2>

      <ul>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/38362342/" target="_blank">
            Cardiomyocyte alpha-1A adrenergic receptors mitigate postinfarct remodeling and mortality by constraining necroptosis (2024)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/38331556/" target="_blank">
            The alpha-1A adrenergic receptor regulates mitochondrial oxidative metabolism in the mouse heart (2024)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/37962887/" target="_blank">
            Cardiovascular outcomes of alpha-blockers vs. 5-alpha reductase inhibitors for benign prostatic hyperplasia (2023)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/35170492/" target="_blank">
            Adrenergic receptor regulation of mitochondrial function in cardiomyocytes (2022)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/33275531/" target="_blank">
            Cardiac alpha-1A adrenergic receptors: emerging protective roles in cardiovascular diseases (2020)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/29051215/" target="_blank">
            Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart (2017)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/28977680/" target="_blank">
            Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism (2017)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/28640223/" target="_blank">
            Non-targeted metabolomics analysis of tyrosine kinase inhibitors sunitinib and erlotinib (2017)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/34756888/" target="_blank">
            The nuclear receptor ROR-alpha preserves cardiomyocyte mitochondrial function by regulating caveolin-3-mediated mitophagy (2021)
          </a>
        </li>
        <li>
          <a href="https://pubmed.ncbi.nlm.nih.gov/30387679/" target="_blank">
            The nuclear receptor ROR-alpha protects against angiotensin II-induced cardiac hypertrophy and heart failure (2018)
          </a>
        </li>
      </ul>

      <p>For a full list of publications by Dr. Brian Jensen, please visit 
        <a href="https://pubmed.ncbi.nlm.nih.gov/?term=jensen+brian+c&sort=date" target="_blank">
          PubMed
        </a>.
      </p>

    </section>
  </main>

  <footer>
    <p>&copy; 2025 Jensen Lab | UNC Chapel Hill</p>
  </footer>
</body>
</html>
